Clovis Oncology, Inc.
CLVSQ
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Net Income | 16.90% | -7.35% | 9.22% | 34.93% | 14.32% |
| Total Depreciation and Amortization | -6.53% | -14.93% | -14.19% | -2.58% | 0.05% |
| Total Amortization of Deferred Charges | -8.12% | -9.66% | -12.68% | -8.43% | -4.50% |
| Total Other Non-Cash Items | 5.68% | 84.64% | 42.39% | -80.91% | -48.82% |
| Change in Net Operating Assets | -49.68% | 116.10% | -129.01% | 2,069.13% | 33.86% |
| Cash from Operations | 11.85% | 24.87% | 5.49% | 26.24% | 15.20% |
| Capital Expenditure | 0.00% | -27.78% | 47.46% | 73.46% | -368.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00% | -27.78% | 47.46% | 73.46% | -368.42% |
| Total Debt Issued | -41.58% | -34.39% | -33.19% | -86.44% | -36.45% |
| Total Debt Repaid | -- | -- | -- | 100.00% | -17,216.67% |
| Issuance of Common Stock | -100.00% | -99.47% | 105,959.26% | 595.34% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | 100.00% |
| Cash from Financing | 150.12% | -89.36% | 183.02% | -81.67% | -176.29% |
| Foreign Exchange rate Adjustments | -858.95% | -1,327.82% | 27.85% | -7,000.00% | -84.23% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 37.76% | -170.42% | 57.03% | -283.69% | -58.59% |
